🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 Wow! #ASCO25 ASCO was absolutely massive! 10 NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

Very pleased that we @UCL are supporting this important new national programme to attract the brightest AI talent from the UK & overseas UCL to host AI scholars as part of UK Government's tech talent programme | UCL News - UCL – University College London ucl.ac.uk/news/2025/jun/…

🙏 Honored to be invited to the 10th @EconomistImpact World Cancer Series Europe in Brussels to discuss how mRNA cancer vaccines could help shape the next era of cancer treatment—interviewed by Elizabeth Sukkar, among health policymakers, pharma leaders & cancer experts. #CancerVaccines

👀 Looking forward to BTOG ASCO 2025 update 📆 Monday 16th June, 6.30pm 🎥 Webinar. See btog.org to register 💰 Don’t be silly! It’s free! 👥 Featuring an all star cast 👇 👊👊

Here’s Charlie from our trustee team at the Lung Cancer Nursing UK Conference today. It’s so important for us to be here, connecting with #lungcancer nurses & having the conversations that really matter for people living with EGFR+. Great agenda lined up - we’re looking forward to the next

FDA grants accelerated approval for datopotamab deruxtecan, anti-TROP2 ADC, for #EGFR mutant NSCLC after prior TKI and chemotherapy. An active agent, based on TROPION-Lung01 and 05. Important toxicities include stomatitis and ocular effects. ascopost.com/news/june-2025…

Looking for a fully funded PhD at the cutting-edge of brain cancer, neuroscience and neuro-degeneration ? Find out more about this CRUK funded position at UCL, and apply to here: ucl.ac.uk/medical-scienc…

Excited to share our new paper with Sheila's lab: we performed an in vivo genome-wide CRISPRa screen using a lung TRACERx PDX model to uncover drivers of brain metastasis. BACE1 emerged as a key hit - especially interesting given ongoing therapeutic efforts in Alzheimer’s.

🆕 Nature study on #lungcancer in never-smokers challenges long-held assumptions. ✅ Air pollution linked to key mutations ✅ EGFR most common in East Asia ❌ Secondhand smoke not a major factor - minimal genomic impact 68% of our EGFR+ UK members (2024 data) are never-smokers

Great to get the band back together again (Photo minus Alastair Greystoke ) in planning for #CONCORDE 2 Great meeting in #Glasgow to strategise and consider outputs from this highly innovative platform study. Huge 🙏 to our PPI reps and to CONCORDE Trial for organising CRUK Lung Centre

Great to see Krijn Dijkstra's work from The Francis Crick Institute published! He developed clonal organoid lines from NSCLC tumours and PDX models. Immune evasion varied between clones from the same tumour, highlighting intratumour heterogeneity and providing a model to study it.

ABSTRACT submission deadline now extended to July 11th! Register now to join us at this exciting Meeting and Hackathon. cvent.me/94L9A5 Oxford, Sept 29th - Oct 1st 2025 #Tcells #AI #Immunology #Oxford #Hackathon

📢 Looking for a theory postdoc to join us The Francis Crick Institute and UCL Physics UCL IPLS. Growth, dynamical systems, patterning, mechanics. Amazing scientific community, career development+collaborations. Drop me a line if interested and spread the word / repost 🙏 ucl.ac.uk/work-at-ucl/se…

This BTOG Essential Update will cover the past, present and future of lung cancer screening in the UK. Including a patient perspective, debates, hot topics, and panels and looking at the challenges and peer support. You can now view the draft programme online. Registration is

Very grateful to everyone who came to the IASLC and ESTRO joint session on management of rare thoracic tumours. Great questions from the attendees. Webinar available online soon!

Great to see Kishen Patel from UCL Cancer Institute as a new addition to the BTOG steering committee as a trainee representative.

ROS1+ Patients (UK) – Next-Line TKIs As discussed, I kindly request Dr. Newsom Davis (Tom Newsom-Davis) to share the following information with oncologists: UK ROS1-positive patients currently have two next-line treatment options: Option 1) NVL-520: An Expanded Access Program

🌟 Delighted to welcome our 4 new BTOG Trainee Representatives 🎉 Tanya 🎉 Kishen 🎉 Paolo 🎉 Michiala They were so good we couldn’t choose just two Looking forward to our first meeting The future of 🇬🇧 respiratory & oncology medicine is clearly very bright 🤗

Thank you to Puneeth Iyengar for an excellent presentation today on Radical Management of Oligometastatic Lung Cancer! Listen on Spotify: open.spotify.com/episode/04iPH2… Subscribe on Spotify: creators.spotify.com/pod/show/virtu… Eric Lim AstraZeneca Medtronic

Thanks to Steven David for flagging this paper to me Authors suggest that #radiotherapy / #SABR in treatment of oligometastatic disease in trials such as the CURB HALT and AVATAR-2 studies should be termed "strategic radiotherapy" Will it catch on? 🔗sciencedirect.com/science/articl…